Park, Jinyoung
Cho, Jinhong
Song, Eun Joo
2024-01-19T16:04:39Z
2024-01-19T16:04:39Z
2021-09-02
2020-11
0253-6269
https://pubs.kist.re.kr/handle/201004/117904
The ubiquitin-proteasome system (UPS) plays an important role in the cellular processes for protein quality control and homeostasis. Dysregulation of the UPS has been implicated in numerous diseases, including cancer. Indeed, components of UPS are frequently mutated or abnormally expressed in various cancers. Since Bortezomib, a proteasome inhibitor, received FDA approval for the treatment of multiple myeloma and mantle cell lymphoma, increasing numbers of researchers have been seeking drugs targeting the UPS as a cancer therapeutic strategy. Here, we introduce the essential component of UPS, including ubiquitinating enzymes, deubiquitinating enzymes and 26S proteasome, and we summarize their targets and mechanisms that are crucial for tumorigenesis. In addition, we briefly discuss some UPS inhibitors, which are currently in clinical trials as cancer therapeutics.
English
PHARMACEUTICAL SOC KOREA
MULTIPLE-MYELOMA CELLS
CANCER THERAPEUTIC TARGET
SMALL-MOLECULE INHIBITOR
TUMOR-SUPPRESSOR CYLD
FATTY-ACID SYNTHASE
NF-KAPPA-B
BREAST-CANCER
IN-VIVO
PROMOTES PROLIFERATION
CYCLIN-E
Ubiquitin-proteasome system (UPS) as a target for anticancer treatment
Article
10.1007/s12272-020-01281-8
1
ARCHIVES OF PHARMACAL RESEARCH, v.43, no.11, pp.1144 - 1161
ARCHIVES OF PHARMACAL RESEARCH
43
11
1144
1161
scie
scopus
kci
ART002654749
000588005000001
2-s2.0-85095605596
Chemistry, Medicinal
Pharmacology & Pharmacy
Pharmacology & Pharmacy
Review
MULTIPLE-MYELOMA CELLS
CANCER THERAPEUTIC TARGET
SMALL-MOLECULE INHIBITOR
TUMOR-SUPPRESSOR CYLD
FATTY-ACID SYNTHASE
NF-KAPPA-B
BREAST-CANCER
IN-VIVO
PROMOTES PROLIFERATION
CYCLIN-E
Ubiquitin–
proteasome system (UPS)
E3 ligase
Deubiquitinating enzymes (DUBs)
Proteasome
Cancer
Small molecule inhibitors